Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Efficacy and Safety of ME3183 Administered Orally in Subjects With Moderate to Severe Plaque Psoriasis

NCT05268016 is registered in ClinicalTrials.gov with Meiji Pharma USA Inc. as lead sponsor.

NCT NCT05268016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05268016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Efficacy and Safety of ME3183 Administered Orally in Subjects With Moderate to Severe Plaque Psoriasis
Lead sponsor
Meiji Pharma USA Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2022
Completion date
May 31, 2023
Enrollment
132 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis